HB 601 establishes an online portal by May 1, 2026, to assist Medicaid applicants and enrollees. This portal allows designated "community assisters" to help individuals apply for Medicaid coverage and submit required documents. Key functions include enabling assisters to review application status, view department notices, report eligibility changes, and update contact information for their clients. The portal also allows, but does not require, assisters to submit initial applications or redeterminations and upload verification documents. This aims to streamline the application process for individuals seeking Medicaid assistance through community organizations.
HB 687 revises the age range for expanded Medicaid participants who are required to engage in community engagement activities. Previously, participants aged 19 to 55 were subject to this requirement. This bill extends that upper age limit, now requiring individuals from 19 to 62 years old to participate. Affected participants must complete 80 hours per month in activities such as employment, education, work training, or community service, unless they qualify for an exemption. This change directly impacts expanded Medicaid recipients between the ages of 56 and 62.
HB 600 authorizes public and nonpublic schools to maintain a supply of "stock albuterol," a quick-relief asthma medication, for emergency use. This medication can be administered by a school nurse or other authorized school personnel to any individual, student or non-student, experiencing respiratory distress on school grounds or at school-related activities. Schools choosing to keep stock albuterol must develop a protocol for staff training, medication maintenance, and post-administration follow-up, including determining when to make a 9-1-1 emergency call. The bill requires a prescription for the stock albuterol, with the school designated as the patient.
HB 544 revises health insurance laws, affecting health insurance issuers, covered individuals, and state employees/retirees. It prohibits health insurance issuers from retroactively denying coverage for services that received prior approval, with exceptions for fraud or misrepresentation. The bill also allows biologic therapies to be prescribed to minors under 18, even if FDA-approved only for adults, provided the treatment is medically necessary and supported by peer-reviewed medical literature. Furthermore, it amends provisions for state insurance contracts, detailing conditions under which certain state employees, retirees, and their families, as well as legislators and judges, can continue membership in state group health plans.
Senate Bill 495 eliminates the Tobacco Prevention Advisory Board. The bill repeals the specific section of law that established this board. It also amends existing statute to remove the board from the list of entities funded by state special revenue accounts, which are primarily used for tobacco disease prevention programs and the Children's Health Insurance Program. The direct effect is the dissolution of the advisory board, which previously provided guidance for these programs.
SB 82 establishes a new program within Montana's Department of Public Health and Human Services to support individuals under age 55 with severe visual impairments in achieving independent living goals. The bill defines "severe visual impairment" as a disability that significantly hinders daily tasks even with correction, and outlines specific services including mobility training, Braille instruction, assistive technology, and peer counseling. Eligibility is determined by the department based on established criteria, with services provided based on available funds and consumer needs, while also guaranteeing a fair hearing for those disagreeing with decisions. The program takes effect July 1, 2025, and applies to Montana residents meeting the defined criteria.
HB 41 adds gabapentin to Montana's Schedule V list of controlled substances under the "depressants" category. This change directly affects medical providers who prescribe gabapentin (used for nerve pain, seizures, and other conditions), pharmacists who dispense it, and patients using the medication. The bill amends Montana Code § 50-32-232 to explicitly include gabapentin - identified by its chemical name "1-(aminomethyl)cyclohexaneacetic acid" - in Schedule V depressants alongside drugs like pregabalin. This policy update standardizes gabapentin's regulatory classification without altering its medical use or prescribing rules.